Skip to main content
. 2021 Jun 17;28(3):419–426. doi: 10.1007/s10880-021-09776-2

Table 1.

Demographic and clinical characteristics of the total sample and divided in absence/presence of psychiatric disorder

Total (n = 245) No psychiatric disorder (n = 156) Psychiatric disorder (n = 89)
M (SD) M (SD) M (SD) P
Age, M (SD) 51.7 (10.7) 51.8 (10.8) 51.4(10.5) .797
Time since diagnosis (years) 3.5 (4.7) 3.4 (4.0) 3.6 (5.7) .755
Psychological distress level  <.001
 HADS total 17.7 (6.6) 15.2 (5.8) 21.9 (5.7)
Fear of cancer recurrence .011
 FCRI-SF 21.3 (6.5) 20.5 (6.7) 22.7 (5.9)
N (%) N(%) N (%)
Gender .665
 Male 35 (14.3) 21(13.5) 14 (15.6)
 Female 210 (85.7) 134(86.5) 76 (84.4)
Relationship .143
 Yes: Married, living together 202 (82.4) 132 (85.2) 70 (77.8)
 No: Divorced / widow/ single 43(17.6) 23 (14.8) 20 (22.2)
Educational level .575
 Low/Intermediate 79 (32.2) 48 (31.0) 31(34.4)
 High 166 (67.8) 107 (69.0) 59 (65.6)
Diagnosis .179
 Breast 151(61.6) 97 (62.2) 54 (60.0)
 Gynecological 18 (7.3) 14 (9.0) 4 (4.4)
 Colon 12 (4.9) 9 (5.8) 4 (3.3)
 Non-Hodgkin 11(4.5) 8 (5.2) 3 (3.3)
 Prostate 16 (6.5) 10 (6.5) 6 (6.7)
 Other 37 (15.1) 17 (11.0) 20 (22.2)
Treatment intent .399
 Curative 206 (84.1) 128 (82.6) 78 (86.7)
 Palliative 39 (15.9) 27 (17.4) 12 (13.3)
Active anticancer treatment .962
 None 129 (52.7) 81 (52.3) 48 (53.3)
 Hormone 79 (32.2) 48 (31.0) 31 (34.4)
 Chemotherapy/Radiation 12(4.9) 8 (4.1) 4 (4.4)
 Other 23 (10.4) 18 (1.6) 7 (7.7)
Psychopharmacological treatment  <.001
 Yes 70 (28.6) 31(19.9) 39 (43.8)
 No 175 (71.4) 125 (80.1) 50 (56.2)